1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Hemophilia A– Epidemiology—2030

Hemophilia A– Epidemiology—2030

  • February 2027
  • 120 pages
  • ID: 5843738
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

Hemophilia A– Epidemiology—2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Hemophilia A – Disease Understanding and Treatment Algorithm
Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII (FVIII). This clotting factor is a part of the intrinsic pathway of blood coagulation. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male.
The symptoms of Hemophilia A can vary greatly from one person to another, it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.
Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A. Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VII are also approved for the treatment of hemophilia A. In some cases, subjects with hemophilia A may develop ‘inhibitors’ against the replacement factor VIII. Inhibitors are antibodies, which are specialized proteins created by the body’s immune system to combat foreign or invading substances such as toxins or bacteria. The immune system may recognize replacement factor VIII as ‘foreign’ and create these antibodies (inhibitors), which target and destroy the replacement factor. For inhibitors treatment is mainly dependent on bypassing agents and immne tolerance therapy (ITI).

Hemophilia A–Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors] scenario of Hemophilia A in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Analysts have assessed that the total prevalent population of Hemophilia A in the 7MM was 42,458 in 2017. In addition to this, it was accessed that the total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.
Estimate suggests that the United States witnessed the highest number of cases with Hemophilia A, as compared to other 7MM countries. As per estimates, the country accounted for approximately 14,200 cases in 2017. Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy. On the other hand, the Spain had the lowest prevalent population of Hemophilia A in 2017. Furthermore, Japan had 5,297 prevalent cases for Hemophilia A in 2017.
It was also observed that Severe Hemophilia A cases are more prominent in comparison to Mild and Moderate. In the United States, observed number of mild cases were 3,195, i.e., 25% of the diagnosed and Treated Hemophilia A patient pool in 2017. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool. Among the Hemophilia A patients, i.e., with or without/Non-Inhibitors, the latter one accounts for a higher number of Hemophilia A cases.
Report Scope
• The report covers a detailed overview of Hemophilia A explaining its causes, symptoms, classification, and pathophysiology.
• The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors.

Hemophilia A Report Key Strengths
• 11–Year Forecast
• 7MM Coverage
• Total Prevalence of Hemophilia A
• Diagnosed and Treated Prevalent Population of Hemophilia A
• Severity-Specific Prevalence of Hemophilia A
• Prevalence of Hemophilia A with Inhibitors and without Inhibitors

Hemophilia A Report Assessment
• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2027

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on